|Mr. Bruce C. Cozadd||Co-Founder, Chairman & CEO||1.97M||N/A||1964|
|Mr. Daniel N. Swisher Jr.||Pres & COO||1.15M||N/A||1963|
|Mr. Matthew P. Young||Exec. VP & CFO||950.35k||560.15k||1969|
|Mr. Michael P. Miller||Exec. VP of US Commercial||811.93k||N/A||1957|
|Ms. Karen J. Wilson||Sr. VP of Fin. & Principal Accounting Officer||N/A||N/A||1963|
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals plc’s ISS Governance QualityScore as of July 29, 2019 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 8.